Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson's disease patients

Nuclear Medicine and Biology

Volumn 41, Issue 4, 2014, Pages 322-329

  Hsiao, Ing Tsung ^a,b   Weng, Yi Hsin ^a,b   Lin, Wey Yil ^b   Hsieh, Chia Ju ^a   Wey, Shiaw Pyng ^a,b   Yen, Tzu Chen ^a,b   Kung, Mei Ping ^c   Lu, Chin Song ^a,b   Lin, Kun Ju ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

DAT; Parkinson's disease; VMAT2

Indexed keywords

FLORBENAZINE F 18; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; TECHNETIUM COMPLEX; TECHNETIUM TC 99M TRODAT 1; TECHNETIUM TC 99M TRODAT-1; TETRABENAZINE; TROPANE DERIVATIVE; VESICULAR MONOAMINE TRANSPORTER 2;

ADULT; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE QUALITY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; QUANTITATIVE ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; (18)F-AV-133; (99M)TC-TRODAT-1; AGED; AMPLITUDE TEST; CASE CONTROL STUDY; COMPARATIVE STUDY; IMAGE PROCESSING; METHODOLOGY; SCINTISCANNING;

(18)F-AV-133; (99M)TC-TRODAT-1; DAT; PARKINSON'S DISEASE; VMAT2;

AGED; CASE-CONTROL STUDIES; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TETRABENAZINE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84895479890     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.12.017     Document Type: Article

References (47)

1. Marttila R.J., Rinne U.K. Dementia in Parkinson's disease. Acta Neurol Scand 1976, 54:431-441.
2. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999, 56:33-39.
3. Geng Y., Shi G.H., Jiang Y., Xu L.X., Hu X.Y., Shao Y.Q. Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson's disease. J Zhejiang Univ Sci B 2005, 6:22-27.
4. Hwang W.J., Yao W.J., Wey S.P., Ting G. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. J Nucl Med 2004, 45:207-213.
5. Koeppe R.A., Gilman S., Joshi A., Liu S., Little R., Junck L., et al. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med 2005, 46:936-944.
6. Okamura N., Villemagne V.L., Drago J., Pejoska S., Dhamija R.K., Mulligan R.S., et al. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med 2010, 51:223-228.
7. Wilson J.M., Levey A.I., Rajput A., Ang L., Guttman M., Shannak K., et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996, 47:718-726.
8. Kaufman M.J., Madras B.K. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 1991, 9:43-49.
9. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000, 47:493-503.
10. Frost J.J., Rosier A.J., Reich S.G., Smith J.S., Ehlers M.D., Snyder S.H., et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993, 34:423-431.
11. Asenbaum S., Brucke T., Pirker W., Podreka I., Angelberger P., Wenger S., et al. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med 1997, 38:1-6.
12. Booij J., Tissingh G., Boer G.J., Speelman J.D., Stoof J.C., Janssen A.G., et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997, 62:133-140.
13. Kung H.F., Kim H.J., Kung M.P., Meegalla S.K., Plossl K., Lee H.K. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur J Nucl Med 1996, 23:1527-1530.
14. Weng Y.H., Yen T.C., Chen M.C., Kao P.F., Tzen K.Y., Chen R.S., et al. Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J Nucl Med 2004, 45:393-401.
15. Lu C.S., Weng Y.H., Chen M.C., Chen R.S., Tzen K.Y., Wey S.P., et al. 99mTc-TRODAT-1 imaging of multiple system atrophy. J Nucl Med 2004, 45:49-55.
16. Brooks D.J. The early diagnosis of Parkinson's disease. Ann Neurol 1998, 44:S10-S18.
17. Wu Y., Le W., Jankovic J. Preclinical biomarkers of Parkinson disease. Arch Neurol 2011, 68:22-30.
18. Huang W.S., Lin S.Z., Lin J.C., Wey S.P., Ting G., Liu R.S. Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging. J Nucl Med 2001, 42:1303-1308.
19. O'Brien J.T., Colloby S., Fenwick J., Williams E.D., Firbank M., Burn D., et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004, 61:919-925.
20. Isaias I.U., Canesi M., Benti R., Gerundini P., Cilia R., Pezzoli G., et al. Striatal dopamine transporter abnormalities in patients with essential tremor. Nucl Med Commun 2008, 29:349-353.
21. Mozley P.D., Schneider J.S., Acton P.D., Plossl K., Stern M.B., Siderowf A., et al. Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 2000, 41:584-589.
22. Yen T.C., Lu C.S., Tzen K.Y., Wey S.P., Chou Y.H., Weng Y.H., et al. Decreased dopamine transporter binding in Machado-Joseph disease. J Nucl Med 2000, 41:994-998.
23. Nirenberg M.J., Chan J., Liu Y., Edwards R.H., Pickel V.M. Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J Neurosci 1996, 16:4135-4145.
24. Martin W.R., Wieler M., Stoessl A.J., Schulzer M. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol 2008, 63:388-394.
25. Wilson J.M., Kish S.J. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 1996, 16:3507-3510.
26. Kilbourn M.R., Frey K.A., Vander Borght T., Sherman P.S. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. Nucl Med Biol 1996, 23:467-471.
27. Albin R.L., Koeppe R.A., Bohnen N.I., Nichols T.E., Meyer P., Wernette K., et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology 2003, 61:310-315.
28. Huang W.S., Chiang Y.H., Lin J.C., Chou Y.H., Cheng C.Y., Liu R.S. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients. J Nucl Med 2003, 44:999-1005.
29. Chen M.K., Kuwabara H., Zhou Y., Adams R.J., Brasic J.R., McGlothan J.L., et al. VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem 2008, 105:78-90.
30. Doudet D.J., Rosa-Neto P., Munk O.L., Ruth T.J., Jivan S., Cumming P. Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study. Neuroimage 2006, 30:26-35.
31. Tian L., Karimi M., Loftin S.K., Brown C.A., Xia H., Xu J., et al. No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease. PLoS One 2012, 7:e31439.
32. Goetz C.G., Poewe W., Rascol O., Sampaio C., Stebbins G.T., Counsell C., et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004, 19:1020-1028.
33. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
34. Tzen K.Y., Lu C.S., Yen T.C., Wey S.P., Ting G. Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1. J Nucl Med 2001, 42:408-413.
35. Kung M.P., Hou C., Goswami R., Ponde D.E., Kilbourn M.R., Kung H.F. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol 2007, 34:239-246.
36. Lin K.J., Lin W.Y., Hsieh C.J., Weng Y.H., Wey S.P., Lu C.S., et al. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements. Nucl Med Biol 2011, 38:1149-1155.
37. Lin K.J., Weng Y.H., Wey S.P., Hsiao I.T., Lu C.S., Skovronsky D., et al. Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent. J Nucl Med 2010, 51:1480-1485.
38. Mazziotta J.C., Toga A.W., Evans A., Fox P., Lancaster J. A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM). Neuroimage 1995, 2:89-101.
39. Andringa G., Eshuis S., Perentes E., Maguire R.P., Roth D., Ibrahim M., et al. TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates. Neurobiol Dis 2003, 14:205-217.
40. Kilbourn M.R., Kuszpit K., Sherman P. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse 2000, 35:250-255.
41. Huang W.S., Lee M.S., Lin J.C., Chen C.Y., Yang Y.W., Lin S.Z., et al. Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson's disease. Eur J Nucl Med Mol Imaging 2004, 31:155-161.
42. Bao S.Y., Wu J.C., Luo W.F., Fang P., Liu Z.L., Tang J. Imaging of dopamine transporters with technetium-99m TRODAT-1 and single photon emission computed tomography. J Neuroimaging 2000, 10:200-203.
43. Eiden L.E., Schafer M.K., Weihe E., Schutz B. The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflugers Arch 2004, 447:636-640.
44. Braak H., Rub U., Gai W.P., Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003, 110:517-536.
45. Forno L.S. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996, 55:259-272.
46. Okawa M., Miwa H., Kajimoto Y., Hama K., Morita S., Nakanishi I., et al. Transcranial sonography of the substantia nigra in Japanese patients with Parkinson's disease or atypical parkinsonism: clinical potential and limitations. Intern Med 2007, 46:1527-1531.
47. Kemmerer E.S., Desmond T.J., Albin R.L., Kilbourn M.R., Frey K.A. Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole. Exp Neurol 2003, 183:81-86.